Article
Cell Biology
Li Liu, Shengchun Liu, Haojun Luo, Chenxi Chen, Xiaoling Zhang, Lin He, Gang Tu
Summary: Resistance to Tamoxifen in ER alpha+ breast cancer patients is mediated by G-protein-coupled estrogen receptor GPR30/GPER, which upregulates HMGB1 expression and secretion in cancer associated fibroblasts (CAFs) to induce autophagy and enhance resistance to TAM in an ERK-dependent manner. Targeting GPR30 and downstream cascades may be an effective strategy to overcome this resistance.
Article
Biochemistry & Molecular Biology
Mayuko Ikarashi, Junko Tsuchida, Masayuki Nagahashi, Shiho Takeuchi, Kazuki Moro, Chie Toshikawa, Shun Abe, Hiroshi Ichikawa, Yoshifumi Shimada, Jun Sakata, Yu Koyama, Nobuaki Sato, Nitai C. Hait, Yiwei Ling, Shujiro Okuda, Kazuaki Takabe, Toshifumi Wakai
Summary: Elevated plasma levels of S1P are associated with larger tumor size, lymph node metastasis, and advanced cancer stage in ER-positive breast cancer patients, indicating a role in cancer progression. Treatment with FTY720, a functional antagonist of S1P receptors, showed promising results in suppressing viability of hormone therapy-resistant cells, suggesting a potential new therapeutic strategy for ER-positive breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Reema S. Wahdan-Alaswad, Susan M. Edgerton, Hiba Salem, Hyun Min Kim, Aik Choon Tan, Jessica Finlay-Schultz, Elizabeth A. Wellberg, Carol A. Sartorius, Britta M. Jacobsen, Bryan R. Haugen, Bolin Liu, Ann D. Thor
Summary: The study revealed clinically significant adverse interactions between THRT, estrogenic, and oncogenic signaling in patients with steroid receptor-positive, lymph node-negative breast cancer.
CLINICAL CANCER RESEARCH
(2021)
Article
Cell Biology
Zhiguo Niu, Jianing Fan, Fengzhe Chen, Huijie Yang, Xin Li, Ting Zhuang, Chunlei Guo, Qi Cao, Jian Zhu, Hui Wang, Qingsong Huang
Summary: Breast cancer is the most common malignancy in women globally. Abnormal expression of RBCK1 protein in breast tumors makes it a valuable diagnostic marker and drug target. Hypoxic regions in breast cancer activate the HIF1 pathway, influencing tumor recurrence and metastasis. Targeting RBCK1 could be a promising treatment strategy for ER-positive breast cancer.
CELL DEATH & DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Chien-Yu Huang, Po-Li Wei, G. M. Shazzad Hossain Prince, Uyanga Batzorig, Cheng-Chin Lee, Yu-Jia Chang, Chin-Sheng Hung
Summary: This study aims to evaluate the role of thrombomodulin (TM) in ER-positive (ER+) breast cancer. The results showed that lower TM expression is associated with poor overall survival and relapse-free survival rates in ER+ breast cancer patients. Silencing TM in MCF7 cells increased cell proliferation, migration, and invasion ability, while overexpression of TM in T47D cells led to decreased cell proliferation, migration, and invasion ability. Furthermore, TM regulates curcumin sensitivity by interfering with the expression of drug-resistant genes.
Article
Food Science & Technology
Lorena V. Zarate, Noelia V. Miret, Alejandro J. Nicola Candia, C. Daniel Zappia, Carolina A. Pontillo, Florencia A. Chiappini, Federico Monczor, Marianela Candolfi, Andrea S. Randi
Summary: Breast cancer is a common cancer among women worldwide, and there is increasing interest in the impact of pesticides on its progression. This study found that exposure to Hexachlorobenzene (HCB), a pesticide, promoted migration and invasion in triple-negative breast cancer cells. The study also revealed that HCB altered the levels of certain receptors and enzymes, contributing to the progression of HER2-positive breast cancer.
FOOD AND CHEMICAL TOXICOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Julia N. Cheng, Jennifer B. Frye, Susan A. Whitman, Andrew G. Kunihiro, Ritu Pandey, Janet L. Funk
Summary: The study found that tumoral Smad-mediated TGF beta signaling plays a role in driving osteolytic bone metastases in estrogen receptor-positive (ER+) breast cancer. Additionally, the combination of TGF beta and estrogen induced PTHrP expression, leading to bone resorption, and treatment with a pan-TGF beta neutralizing antibody decreased osteolytic ER+ bone metastases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, Research & Experimental
Lei Wang, Jia Yi, Ling-yun Lu, Yue-ying Zhang, Lan Wang, Guo-sheng Hu, Yi-chen Liu, Jian-cheng Ding, Hai-feng Shen, Fang-qing Zhao, Hai-hua Huang, Wen Liu
Summary: The study revealed that estrogen can induce a circRNA program, with circPGR playing a crucial role in ER-positive breast cancer cell growth and tumorigenesis by acting as a ceRNA for miR-301a-5p to regulate cell cycle genes.
Review
Oncology
Suryendu Saha, Samya Dey, Somsubhra Nath
Summary: This article discusses the role of steroid hormone receptors in cell cycle regulation, with a focus on their interaction with breast cancer.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Fei Fei, Gene P. Siegal, Shi Wei
Summary: The study analyzed clinicopathologic features and clinical outcomes of ER-low-positive breast cancers. ER-low-positive tumors showed significantly better prognosis compared to ER-negative tumors, with overlapping survival outcomes with ER-positive tumors in the entire cohort.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Jin Young Min, Gi Ho Lee, Tilak Khanal, Sun Woo Jin, Sang-Yeop Lee, Hyung Gyun Kim, Ju-Yong Hyon, Young-Ho Chung, Sang Keun Ha, Eun Hee Han, Hye Gwang Jeong
Summary: This study investigated the correlation between hypoxia and CYP1B1 expression in breast cancer cells, finding that hypoxia induced CYP1B1 in ERα-positive breast cancer cells. HIF-1α activated ERα through direct binding, promoting CYP1B1 expression.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Cell Biology
Reema S. Wahdan-Alaswad, Susan M. Edgerton, Hyun Min Kim, Aik Choon Tan, Bryan R. Haugen, Bolin Liu, Ann D. Thor
Summary: Expression and signaling of estrogen receptor (ERα) play a major role in breast cancer development. Interactions with thyroid hormones and their receptors can lead to endocrine therapy resistance. A study found that thyroid hormone replacement therapy is significantly associated with higher rates of relapse and mortality in breast cancer patients, especially those who are steroid receptor positive and node-negative. In in vivo and in vitro experiments, researchers discovered that thyroid hormone in combination with estrogen and tamoxifen can enhance cell proliferation and resistance to tamoxifen in breast cancer cells.
Article
Medicine, General & Internal
Jingkai Xu, Guozheng Li, Mengyun Chen, Wenjing Li, Yaxing Wu, Xuejun Zhang, Yong Cui, Bo Zhang
Summary: Genetic testing is widely used in breast cancer and a recent study has found a genetic association between rs12537 and breast cancer. The rs12537 variant is significantly correlated with ER positive patients.
FRONTIERS IN MEDICINE
(2021)
Article
Medicine, Research & Experimental
Ipshita Nandi, Harvey W. Smith, Virginie Sanguin-Gendreau, Linjia Ji, Alain Pacis, Vasilios Papavasiliou, Dongmei Zuo, Stella Nam, Sherif S. Attalla, Sung Hoon Kim, Sierra Lusson, Hellen Kuasne, Anne -Marie Fortier, Paul Savage, Constanza Martinez Ramirez, Morag Park, John A. Katzenellenbogen, Benita S. Katzenellenbogen, William J. Muller
Summary: Activation of c-Src promotes breast cancer progression by phosphorylating FOXM1 on 2 tyrosine residues, stimulating its nuclear localization and target gene expression. The positive feedback loop formed by c-Src and FOXM1 drives proliferation in luminal B-like breast cancer. Targeting this mechanism induces cell-cycle arrest, apoptosis, and blocks tumor progression in luminal breast cancers.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Medicine, General & Internal
Ioannis A. Voutsadakis
Summary: This study investigates ER-positive/HER2-negative or luminal breast cancers with high mutation numbers and compares them with cancers of the same subtype and low mutation numbers. The results show that breast cancers with high mutation numbers have a higher prevalence of certain genetic mutations and DNA damage response genes. However, the prognosis of these breast cancers is not significantly different compared to those with lower mutation counts. These findings provide information on the suitability of these cancers for immunotherapy and potential combination therapies.
JOURNAL OF CLINICAL MEDICINE
(2022)
Meeting Abstract
Oncology
Gokul M. Das, Utpal K. Mukhopadhyay, Christina Adams, Nadi Wickramasekera, Rajesh Medisetty, Sanjay Bansal, Laxmi Silwal-Pandit, Anne-Lise Borresen-Dale, Austin Miller, Wendy M. Sweizig, Angela Omilian, Wiam Bshara, Alka Mukhopadhyay
Meeting Abstract
Oncology
Kwang Hwa Jung, Jun Hyoung Park, Tirupataiah Sirupangi, Dongya Jia, Shivanand Pudakalakatti, Nishant Gandhi, Jessica Elswood, Vasanta Putluri, Chad J. Creighton, Weston Porter, Michael T. Lewis, Xi Chen, Nagireddy Putluri, Pratip K. Bhattacharya, Lee-Jun C. Wong, Gokul M. Das, Benny A. Kaipparettu
Review
Cell Biology
Nishant Gandhi, Gokul M. Das
Article
Oncology
Utpal K. Mukhopadhyay, Chetan C. Oturkar, Christina Adams, Nadi Wickramasekera, Sanjay Bansal, Rajesh Medisetty, Austin Miller, Wendy M. Swetzig, Laxmi Silwal-Pandit, Anne-Lise Borresen-Dale, Chad J. Creighton, Jun Hyoung Park, Santhi D. Konduri, Alka Mukhopadhyay, Alexander Caradori, Angela Omilian, Wiam Bshara, Benny Abraham Kaipparettu, Gokul M. Das
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2019)
Article
Oncology
Nishant Gandhi, Chetan C. Oturkar, Gokul M. Das
Summary: The study explores the mechanisms of action of ERα, p53 mutations, and AMPK in breast cancer therapy. Understanding the key regulatory pathways involved can help overcome therapeutic resistance and improve the efficacy of endocrine therapy against luminal breast cancer.
Article
Oncology
Chetan C. Oturkar, Nishant Gandhi, Pramod Rao, Kevin H. Eng, Austin Miller, Prashant K. Singh, Emese Zsiros, Kunle O. Odunsi, Gokul M. Das
Summary: High grade serous ovarian cancer (HGSOC) is a common and deadly subtype of ovarian cancer with a high prevalence of mutant p53. This study investigated the interaction between estrogen receptor-beta (ER beta) and mutant p53 in HGSOC. The researchers found that ER beta 2 and mutant p53 co-dependently regulated the transcription of the FOXM1 gene, leading to increased cell proliferation and resistance to treatment. High levels of ER beta 2 and FOXM1 were correlated with worse patient survival. This suggests that targeting the ER beta 2-mutant p53-FOXM1 axis could be a novel therapeutic strategy for HGSOC.
Article
Medicine, General & Internal
Shanker Kundumadam, Hansini Laharwani, Shafeek Azhikkalayil, Gokul Das
CUREUS JOURNAL OF MEDICAL SCIENCE
(2020)
Correction
Oncology
B. A. Kaipparettu, S. Malik, S. D. Konduri, W. Liu, M. Rokavec, H. van der Kuip, R. Hoppe, S. Hammerich-Hille, P. Fritz, W. Schroth, I Abele, G. M. Das, S. Oesterreich, H. Brauch
INTERNATIONAL JOURNAL OF CANCER
(2019)
Meeting Abstract
Oncology
K. H. Jung, J. H. Park, T. Sirupangi, D. Jia, N. Gandhi, S. Pudakalakatti, J. Elswood, W. Porter, N. Putluri, X. H-F Zhang, X. Chen, P. K. Bhattacharya, C. J. Creighton, M. T. Lewis, J. M. Rosen, L-J C. Wong, G. M. Das, C. K. Osborne, M. F. Rimawi, B. A. Kaipparettu
Article
Biochemistry & Molecular Biology
Preeti Purwaha, Franklin Gu, Danthasinghe Waduge Badrajee Piyarathna, Theckelnaycke Rajendiran, Anindita Ravindran, Angela R. Omilian, Sao Jiralerspong, Gokul Das, Carl Morrison, Christine Ambrosone, Cristian Coarfa, Nagireddy Putluri, Arun Sreekumar
Meeting Abstract
Oncology
Chetan Oturkar, Austin Miller, Emese Zsiros, Gokul M. Das
CLINICAL CANCER RESEARCH
(2018)
Meeting Abstract
Oncology
G. M. Das, S. Kulkarni, C. Oturkar, S. B. Edge, J. Wang, J. H. Wilton, W. M. Swetzig, A. Adjei, R. Bies, A. D. Hutson, A. Groman, C. D. Morrison, J. Fetterly, S. Kumar, H. H. Cappuccino
Article
Biology
Song Liu, Sangeeta Kumari, Qiang Hu, Dhirodatta Senapati, Varadha Balaji Venkadakrishnan, Dan Wang, Adam D. DePriest, Simon E. Schlanger, Salma Ben-Salem, Malyn May Valenzuela, Belinda Willard, Shaila Mudambi, Wendy M. Swetzig, Gokul M. Das, Mojgan Shourideh, Shahriah Koochekpour, Sara Moscovita Falzarano, Cristina Magi-Galluzzi, Neelu Yadav, Xiwei Chen, Changshi Lao, Jianmin Wang, Jean-Noel Billaud, Hannelore V. Heemers
Meeting Abstract
Oncology
Swati A. Kulkarni, Chetan C. Oturkar, Stephen B. Edge, Jianmin Wang, John H. Walton, Wendy M. Swetzig, Araba Adjei, Robert Bies, Alan D. Hutson, Adrienne Groman, Morrison D. Carl, Jerry Fetterly, Schika Kumar, Gokul M. Das
Meeting Abstract
Oncology
Christina E. Adams, Gokul M. Das